PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Targeting the mTOR pathway in breast cancer.

Abstract Mechanistic target of rapamycin controls cell growth, metabolism, and aging in response to nutrients, cellular energy stage, and growth factors. In cancers including breast cancer, mechanistic target of rapamycin is frequently upregulated. Blocking mechanistic target of rapamycin with rapamycin, first-generation and second-generation mechanistic target of rapamycin inhibitors, called rapalogs, have shown potent reduction of breast cancer tumor growth in preclinical models and clinical trials. In this review, we summarize the fundamental role of the mechanistic target of rapamycin pathway in driving breast tumors. Moreover, we also review key molecules involved with aberrant mechanistic target of rapamycin pathway activation in breast cancer and current efforts to target these components for therapeutic gain. Further development of predictive biomarkers will be useful in the selection of patients who will benefit from inhibition of the mechanistic target of rapamycin pathway.
PMID
Related Publications

Combined SFK/mTOR inhibition prevents rapamycin-induced feedback activation of AKT and elicits efficient tumor regression.

The Mammalian target of rapamycin inhibitors in breast cancer: current evidence and future directions.

New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer.

Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin pathway inhibition: a breakthrough in the management of luminal (ER+/HER2-) breast cancers?

Targeting the mTOR pathway in hepatocellular carcinoma: current state and future trends.

Authors

Mayor MeshTerms

Molecular Targeted Therapy

Keywords

Mechanistic target of rapamycin

breast cancer

clinical trials

diagnostic biomarkers

mechanistic target of rapamycin inhibitors

Journal Title tumour biology : the journal of the international society for oncodevelopmental biology and medicine
Publication Year Start




PMID- 28639903
OWN - NLM
STAT- MEDLINE
DA  - 20170622
DCOM- 20170711
LR  - 20170713
IS  - 1423-0380 (Electronic)
IS  - 1010-4283 (Linking)
VI  - 39
IP  - 6
DP  - 2017 Jun
TI  - Targeting the mTOR pathway in breast cancer.
PG  - 1010428317710825
LID - 10.1177/1010428317710825 [doi]
AB  - Mechanistic target of rapamycin controls cell growth, metabolism, and aging in
      response to nutrients, cellular energy stage, and growth factors. In cancers
      including breast cancer, mechanistic target of rapamycin is frequently
      upregulated. Blocking mechanistic target of rapamycin with rapamycin,
      first-generation and second-generation mechanistic target of rapamycin
      inhibitors, called rapalogs, have shown potent reduction of breast cancer tumor
      growth in preclinical models and clinical trials. In this review, we summarize
      the fundamental role of the mechanistic target of rapamycin pathway in driving
      breast tumors. Moreover, we also review key molecules involved with aberrant
      mechanistic target of rapamycin pathway activation in breast cancer and current
      efforts to target these components for therapeutic gain. Further development of
      predictive biomarkers will be useful in the selection of patients who will
      benefit from inhibition of the mechanistic target of rapamycin pathway.
FAU - Liu, Jia
AU  - Liu J
AD  - Maternal and Child Health Hospital of Qinhuangdao, Qinhuangdao, P.R. China.
FAU - Li, Hui-Qing
AU  - Li HQ
AD  - Maternal and Child Health Hospital of Qinhuangdao, Qinhuangdao, P.R. China.
FAU - Zhou, Fu-Xia
AU  - Zhou FX
AD  - Maternal and Child Health Hospital of Qinhuangdao, Qinhuangdao, P.R. China.
FAU - Yu, Jie-Wen
AU  - Yu JW
AD  - Maternal and Child Health Hospital of Qinhuangdao, Qinhuangdao, P.R. China.
FAU - Sun, Ling
AU  - Sun L
AD  - Maternal and Child Health Hospital of Qinhuangdao, Qinhuangdao, P.R. China.
FAU - Han, Zhong-Hou
AU  - Han ZH
AD  - Maternal and Child Health Hospital of Qinhuangdao, Qinhuangdao, P.R. China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Tumour Biol
JT  - Tumour biology : the journal of the International Society for Oncodevelopmental
      Biology and Medicine
JID - 8409922
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.1.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Breast Neoplasms/drug therapy/*genetics/pathology
MH  - Cell Proliferation/genetics
MH  - Female
MH  - Humans
MH  - *Molecular Targeted Therapy
MH  - Signal Transduction
MH  - Sirolimus/therapeutic use
MH  - TOR Serine-Threonine Kinases/antagonists & inhibitors/*genetics
OTO - NOTNLM
OT  - Mechanistic target of rapamycin
OT  - breast cancer
OT  - clinical trials
OT  - diagnostic biomarkers
OT  - mechanistic target of rapamycin inhibitors
EDAT- 2017/06/24 06:00
MHDA- 2017/07/14 06:00
CRDT- 2017/06/23 06:00
AID - 10.1177/1010428317710825 [doi]
PST - ppublish
SO  - Tumour Biol. 2017 Jun;39(6):1010428317710825. doi: 10.1177/1010428317710825.